Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 425

1.

Isavuconazole as Primary Anti-Fungal Prophylaxis in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective, Phase II Study.

Bose P, McCue D, Wurster S, Wiederhold NP, Konopleva M, Kadia TM, Borthakur G, Ravandi F, Masarova L, Takahashi K, Zeev E, Yilmaz M, Daver N, Pemmaraju N, Naqvi K, Rausch CR, Marx KR, Qiao W, Huang X, Bivins CA, Pierce SA, Kantarjian HM, Kontoyiannis DP.

Clin Infect Dis. 2020 Apr 1. pii: ciaa358. doi: 10.1093/cid/ciaa358. [Epub ahead of print]

PMID:
32236406
2.

Phase 2 Study of Hyper-CMAD with Liposomal Vincristine for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia.

Sasaki K, Kantarjian H, Wierda W, Ravandi F, Daver N, Burger J, DiNardo CD, Jain N, Short NJ, Estrov Z, Konopleva M, Ohanian M, Garcia-Manero G, Kadia T, Alvarado Y, Yilmaz M, Pierce S, Garris R, Cortes J, O'Brien S, Ingram A, Jabbour E.

Am J Hematol. 2020 Mar 14. doi: 10.1002/ajh.25784. [Epub ahead of print]

PMID:
32170867
3.

MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine ± idasanutlin in relapsed or refractory acute myeloid leukemia.

Montesinos P, Beckermann BM, Catalani O, Esteve J, Gamel K, Konopleva MY, Martinelli G, Monnet A, Papayannidis C, Park A, Récher C, Rodríguez-Veiga R, Röllig C, Vey N, Wei AH, Yoon SS, Fenaux P.

Future Oncol. 2020 Mar 13. doi: 10.2217/fon-2020-0044. [Epub ahead of print]

4.

Fatty Acid Metabolism, Bone Marrow Adipocytes, and AML.

Tabe Y, Konopleva M, Andreeff M.

Front Oncol. 2020 Feb 18;10:155. doi: 10.3389/fonc.2020.00155. eCollection 2020. Review.

5.

Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors.

Oran B, Garcia-Manero G, Saliba RM, Alfayez M, Al-Atrash G, Ciurea SO, Jabbour EJ, Mehta RS, Popat UR, Ravandi F, Alousi AM, Kadia TM, Konopleva M, DiNardo CD, Rezvani K, Shpall EJ, Sharma P, Kantarjian HM, Champlin RE, Daver N.

Cancer. 2020 Mar 3. doi: 10.1002/cncr.32796. [Epub ahead of print]

PMID:
32125707
6.

Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy.

Montalban-Bravo G, Kanagal-Shamanna R, Class CA, Sasaki K, Ravandi F, Cortes JE, Daver N, Takahashi K, Short NJ, DiNardo CD, Jabbour E, Borthakur G, Naqvi K, Issa GC, Konopleva M, Khoury JD, Routbort M, Pierce S, Do KA, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G, Kadia TM.

Am J Hematol. 2020 Feb 28. doi: 10.1002/ajh.25769. [Epub ahead of print]

PMID:
32112433
7.

Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia.

Richard-Carpentier G, Jabbour E, Short NJ, Rausch CR, Savoy JM, Bose P, Yilmaz M, Jain N, Borthakur G, Ohanian M, Alvarado Y, Rytting M, Kebriaei P, Konopleva M, Kantarjian H, Ravandi F.

Clin Lymphoma Myeloma Leuk. 2019 Sep 30. pii: S2152-2650(19)31995-0. doi: 10.1016/j.clml.2019.09.608. [Epub ahead of print]

PMID:
32035785
8.

Venetoclax in acute myeloid leukemia - current and future directions.

Lachowiez C, DiNardo CD, Konopleva M.

Leuk Lymphoma. 2020 Feb 7:1-10. doi: 10.1080/10428194.2020.1719098. [Epub ahead of print]

PMID:
32031033
9.

Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes.

Montalban-Bravo G, Kanagal-Shamanna R, Benton CB, Class CA, Chien KS, Sasaki K, Naqvi K, Alvarado Y, Kadia TM, Ravandi F, Daver N, Takahashi K, Jabbour E, Borthakur G, Pemmaraju N, Konopleva M, Soltysiak KA, Pierce SR, Bueso-Ramos CE, Patel KP, Kantarjian H, Garcia-Manero G.

Blood Adv. 2020 Feb 11;4(3):482-495. doi: 10.1182/bloodadvances.2019001101.

10.

Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges.

Short NJ, Konopleva M, Kadia TM, Borthakur G, Ravandi F, DiNardo CD, Daver N.

Cancer Discov. 2020 Apr;10(4):506-525. doi: 10.1158/2159-8290.CD-19-1011. Epub 2020 Feb 3. Review.

PMID:
32014868
11.

Long-term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia.

Masarova L, Cortes JE, Patel KP, O'Brien S, Nogueras-Gonzalez GM, Konopleva M, Verstovsek S, Garcia-Manero G, Ferrajoli A, Kadia TM, Ravandi-Kashani F, Borthakur G, DellaSala S, Estrov Z, Jabbour EJ, Kantarjian HM.

Cancer. 2020 Apr 1;126(7):1448-1459. doi: 10.1002/cncr.32623. Epub 2020 Jan 30.

PMID:
31999850
12.

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.

DiNardo CD, Tiong IS, Quaglieri A, MacRaild S, Loghavi S, Brown FC, Thijssen R, Pomilio G, Ivey A, Salmon JM, Glytsou C, Fleming SA, Zhang Q, Ma H, Patel KP, Kornblau SM, Xu Z, Chua CC, Chen X, Blombery P, Flensburg C, Cummings N, Aifantis I, Kantarjian H, Huang DCS, Roberts AW, Majewski IJ, Konopleva M, Wei AH.

Blood. 2020 Mar 12;135(11):791-803. doi: 10.1182/blood.2019003988.

PMID:
31932844
13.

Venetoclax for AML: changing the treatment paradigm.

Pollyea DA, Amaya M, Strati P, Konopleva MY.

Blood Adv. 2019 Dec 23;3(24):4326-4335. doi: 10.1182/bloodadvances.2019000937.

14.

Correction: Targeting mantle cell lymphoma metabolism and survival through simultaneous blockade of mTOR and nuclear transporter exportin-1.

Sekihara K, Saitoh K, Han L, Ciurea S, Yamamoto S, Kikkawa M, Kazuno S, Taka H, Kaga N, Arai H, Miida T, Andreeff M, Konopleva M, Tabe Y.

Oncotarget. 2019 Nov 26;10(63):6842. doi: 10.18632/oncotarget.27309. eCollection 2019 Nov 26.

15.

A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies.

Phillips DC, Jin S, Gregory GP, Zhang Q, Xue J, Zhao X, Chen J, Tong Y, Zhang H, Smith M, Tahir SK, Clark RF, Penning TD, Devlin JR, Shortt J, Hsi ED, Albert DH, Konopleva M, Johnstone RW, Leverson JD, Souers AJ.

Leukemia. 2019 Dec 11. doi: 10.1038/s41375-019-0652-0. [Epub ahead of print]

PMID:
31827241
16.

Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?

Ciurea SO, Kongtim P, Varma A, Rondon G, Chen J, Srour S, Bashir Q, Alousi A, Mehta R, Oran B, Popat U, Hosing C, Olson A, Daver N, Konopleva M, Champlin RE.

Blood. 2020 Feb 6;135(6):449-452. doi: 10.1182/blood.2019003662.

PMID:
31826244
17.

Features of non-activation dendritic state and immune deficiency in blastic plasmacytoid dendritic cell neoplasm (BPDCN).

Beird HC, Khan M, Wang F, Alfayez M, Cai T, Zhao L, Khoury J, Futreal PA, Konopleva M, Pemmaraju N.

Blood Cancer J. 2019 Dec 6;9(12):99. doi: 10.1038/s41408-019-0262-0.

18.

Role of tagraxofusp in treating blastic plasmacytoid dendritic cell neoplasm (BPDCN).

Alfayez M, Konopleva M, Pemmaraju N.

Expert Opin Biol Ther. 2020 Feb;20(2):115-123. doi: 10.1080/14712598.2020.1701651. Epub 2019 Dec 17.

PMID:
31801379
19.

A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity.

Khan S, Zhang X, Lv D, Zhang Q, He Y, Zhang P, Liu X, Thummuri D, Yuan Y, Wiegand JS, Pei J, Zhang W, Sharma A, McCurdy CR, Kuruvilla VM, Baran N, Ferrando AA, Kim YM, Rogojina A, Houghton PJ, Huang G, Hromas R, Konopleva M, Zheng G, Zhou D.

Nat Med. 2019 Dec;25(12):1938-1947. doi: 10.1038/s41591-019-0668-z. Epub 2019 Dec 2.

PMID:
31792461
20.

AMP-activated protein kinase links acetyl-CoA homeostasis to BRD4 recruitment in acute myeloid leukemia.

Jiang Y, Hu T, Wang T, Shi X, Kitano A, Eagle K, Hoegenauer KA, Konopleva MY, Lin CY, Young NL, Nakada D.

Blood. 2019 Dec 12;134(24):2183-2194. doi: 10.1182/blood.2019001076.

PMID:
31697807
21.

The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival.

Yilmaz M, Kantarjian H, Wang X, Khoury JD, Ravandi F, Jorgensen J, Short NJ, Loghavi S, Cortes J, Garcia-Manero G, Kadia T, Sasaki K, Konopleva M, Takahashi K, Wierda W, Jain N, Verstovsek S, Estrov Z, Bose P, Pierce S, Garris R, O'Brien S, Jabbour E.

Am J Hematol. 2020 Feb;95(2):144-150. doi: 10.1002/ajh.25671. Epub 2019 Nov 19.

PMID:
31682008
22.

[Antiviral effect of «Kagocel» substance in vitro on influenza viruses H1N1, H1N1pdm09 and H3N2.]

Fediakina IT, Konopleva MV, Proshina ES, Linnik EV, Nikitina NI.

Vopr Virusol. 2019;64(3):125-131. doi: 10.18821/0507-4088-2019-64-3-125-131. Russian.

PMID:
31622059
23.

[Detection of Epstein-Barr virus genome in oral cavity squamous cell carcinoma samples of russian patients.]

Kiryanov SA, Levina TA, Polyakov AP, Rebrikova IV, Murashko DA, Konopleva MV, Semenenko TA, Suslov AP.

Vopr Virusol. 2019;64(3):112-117. doi: 10.18821/0507-4088-2019-64-3-112-117. Russian.

PMID:
31622057
24.

Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation.

Srour SA, Saliba RM, Bittencourt MCB, Perez JMR, Kongtim P, Alousi A, Al-Atrash G, Olson A, Betul O, Mehta R, Popat U, Hosing C, Bashir Q, Khouri I, Kebriaei P, Masarova L, Short N, Jabbour E, Daver N, Konopleva M, Ravandi F, Kantarjian H, Champlin RE, Ciurea SO.

Am J Hematol. 2019 Dec;94(12):1382-1387. doi: 10.1002/ajh.25647. Epub 2019 Oct 21.

PMID:
31595538
25.

Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors.

Abou Dalle I, Kantarjian HM, Short NJ, Konopleva M, Jain N, Garcia-Manero G, Garris R, Qiao W, Cortes JE, O'Brien S, Kebriaei P, Kadia T, Jabbour E, Ravandi F.

Am J Hematol. 2019 Dec;94(12):1388-1395. doi: 10.1002/ajh.25648. Epub 2019 Oct 21.

PMID:
31595534
26.

Recent developments in the treatment of blastic plasmacytoid dendritic cell neoplasm.

Economides MP, Konopleva M, Pemmaraju N.

Ther Adv Hematol. 2019 Sep 23;10:2040620719874733. doi: 10.1177/2040620719874733. eCollection 2019. Review.

27.

Amino acid metabolism in hematologic malignancies and the era of targeted therapy.

Tabe Y, Lorenzi PL, Konopleva M.

Blood. 2019 Sep 26;134(13):1014-1023. doi: 10.1182/blood.2019001034. Epub 2019 Aug 15. Review.

PMID:
31416801
28.

Percutaneous coronary intervention and in-hospital outcomes in patients with leukemia: a nationwide analysis.

Potts J, Mohamed MO, Lopez Mattei JC, Iliescu CA, Konopleva M, Rashid M, Bagur R, Mamas MA.

Catheter Cardiovasc Interv. 2019 Aug 13. doi: 10.1002/ccd.28432. [Epub ahead of print]

PMID:
31410970
29.

A mechanism for increased sensitivity of acute myeloid leukemia to mitotoxic drugs.

Panina SB, Baran N, Brasil da Costa FH, Konopleva M, Kirienko NV.

Cell Death Dis. 2019 Aug 13;10(8):617. doi: 10.1038/s41419-019-1851-3.

30.

Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.

Ravandi F, Assi R, Daver N, Benton CB, Kadia T, Thompson PA, Borthakur G, Alvarado Y, Jabbour EJ, Konopleva M, Takahashi K, Kornblau S, DiNardo CD, Estrov Z, Flores W, Basu S, Allison J, Sharma P, Pierce S, Pike A, Cortes JE, Garcia-Manero G, Kantarjian HM.

Lancet Haematol. 2019 Sep;6(9):e480-e488. doi: 10.1016/S2352-3026(19)30114-0. Epub 2019 Aug 7.

PMID:
31400961
31.

Targeting PRMT1-mediated FLT3 methylation disrupts maintenance of MLL-rearranged acute lymphoblastic leukemia.

Zhu Y, He X, Lin YC, Dong H, Zhang L, Chen X, Wang Z, Shen Y, Li M, Wang H, Sun J, Nguyen LX, Zhang H, Jiang W, Yang Y, Chen J, Müschen M, Chen CW, Konopleva MY, Sun W, Jin J, Carlesso N, Marcucci G, Luo Y, Li L.

Blood. 2019 Oct 10;134(15):1257-1268. doi: 10.1182/blood.2019002457.

PMID:
31395602
32.

Assessing Metabolic Intervention with a Glutaminase Inhibitor in Real-Time by Hyperpolarized Magnetic Resonance in Acute Myeloid Leukemia.

Zacharias NM, Baran N, Shanmugavelandy SS, Lee J, Lujan JV, Dutta P, Millward SW, Cai T, Wood CG, Piwnica-Worms D, Konopleva M, Bhattacharya PK.

Mol Cancer Ther. 2019 Nov;18(11):1937-1946. doi: 10.1158/1535-7163.MCT-18-0985. Epub 2019 Aug 6.

33.

Three-Dimensional Leukemia Co-Culture System for In Vitro High-Content Metabolomics Screening.

Lu X, Lodi A, Konopleva M, Tiziani S.

SLAS Discov. 2019 Sep;24(8):817-828. doi: 10.1177/2472555219860446. Epub 2019 Jul 25.

PMID:
31345091
34.

Dual Expression of TCF4 and CD123 Is Highly Sensitive and Specific For Blastic Plasmacytoid Dendritic Cell Neoplasm.

Sukswai N, Aung PP, Yin CC, Li S, Wang W, Wang SA, Ortega V, Lyapichev K, Nagarajan P, Alfattal R, Angelova E, Tang Z, Loghavi S, Kanagal-Shamanna R, Miranda RN, Pemmaraju N, Bhalla K, Konopleva M, Medeiros LJ, Khoury JD.

Am J Surg Pathol. 2019 Oct;43(10):1429-1437. doi: 10.1097/PAS.0000000000001316.

PMID:
31261288
35.

Neurotoxic events associated with BCR-ABL1 tyrosine kinase inhibitors: a case series.

Rafei H, Jabbour EJ, Kantarjian H, Sinicrope KD, Kamiya-Matsuoka C, Mehta RS, Daver NG, Kadia TM, Naqvi K, Cortes J, Konopleva M.

Leuk Lymphoma. 2019 Dec;60(13):3292-3295. doi: 10.1080/10428194.2019.1633635. Epub 2019 Jun 27. No abstract available.

PMID:
31246142
36.

Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib.

Yalniz F, Abou Dalle I, Kantarjian H, Borthakur G, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Sasaki K, Daver N, DiNardo C, Pemmaraju N, Short NJ, Yilmaz M, Bose P, Naqvi K, Pierce S, Nogueras González GM, Konopleva M, Andreeff M, Cortes J, Ravandi F.

Am J Hematol. 2019 Sep;94(9):984-991. doi: 10.1002/ajh.25553. Epub 2019 Jun 24.

PMID:
31237017
37.

Antileukemia Effects of Notch-Mediated Inhibition of Oncogenic PLK1 in B-Cell Acute Lymphoblastic Leukemia.

Kannan S, Aitken MJL, Herbrich SM, Golfman LS, Hall MG, Mak DH, Burks JK, Song G, Konopleva M, Mullighan CG, Chandra J, Zweidler-McKay PA.

Mol Cancer Ther. 2019 Sep;18(9):1615-1627. doi: 10.1158/1535-7163.MCT-18-0706. Epub 2019 Jun 21.

38.

Glutaminase Activity of L-Asparaginase Contributes to Durable Preclinical Activity against Acute Lymphoblastic Leukemia.

Chan WK, Horvath TD, Tan L, Link T, Harutyunyan KG, Pontikos MA, Anishkin A, Du D, Martin LA, Yin E, Rempe SB, Sukharev S, Konopleva M, Weinstein JN, Lorenzi PL.

Mol Cancer Ther. 2019 Sep;18(9):1587-1592. doi: 10.1158/1535-7163.MCT-18-1329. Epub 2019 Jun 17.

39.

Venetoclax-based therapies for acute myeloid leukemia.

Guerra VA, DiNardo C, Konopleva M.

Best Pract Res Clin Haematol. 2019 Jun;32(2):145-153. doi: 10.1016/j.beha.2019.05.008. Epub 2019 May 24. Review.

PMID:
31203996
40.

Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia.

Chamoun K, Kantarjian HM, Wang X, Naqvi K, Aung F, Garcia-Manero G, Borthakur G, Jabbour E, Kadia T, Daver N, DiNardo CD, Jain N, Konopleva M, Cortes J, Ravandi F, Yilmaz M.

Cancer. 2019 Sep 15;125(18):3219-3224. doi: 10.1002/cncr.32196. Epub 2019 May 31.

PMID:
31150121
41.

Ibrutinib and Venetoclax for First-Line Treatment of CLL.

Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W.

N Engl J Med. 2019 May 30;380(22):2095-2103. doi: 10.1056/NEJMoa1900574.

PMID:
31141631
42.

Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models.

Han L, Zhang Q, Dail M, Shi C, Cavazos A, Ruvolo VR, Zhao Y, Kim E, Rahmani M, Mak DH, Jin SS, Chen J, Phillips DC, Koller PB, Jacamo R, Burks JK, DiNardo C, Daver N, Jabbour E, Wang J, Kantarjian HM, Andreeff M, Grant S, Leverson JD, Sampath D, Konopleva M.

Haematologica. 2020 Mar;105(3):697-707. doi: 10.3324/haematol.2018.205534. Epub 2019 May 23.

43.

Proteomic Profiling of Signaling Networks Modulated by G-CSF/Plerixafor/Busulfan-Fludarabine Conditioning in Acute Myeloid Leukemia Patients in Remission or with Active Disease prior to Allogeneic Stem Cell Transplantation.

Zeng Z, Liu W, Benton CB, Konoplev S, Lu H, Wang RY, Chen J, Shpall E, Baggerly KA, Champlin R, Konopleva M.

Acta Haematol. 2019;142(3):176-184. doi: 10.1159/000495456. Epub 2019 May 21.

PMID:
31112940
44.

PD1/PD-L1 Expression in Blastic Plasmacytoid Dendritic Cell Neoplasm.

Aung PP, Sukswai N, Nejati R, Loghavi S, Chen W, Torres-Cabala CA, Yin CC, Konopleva M, Zheng X, Wang J, Tang Z, Medeiros LJ, Prieto VG, Pemmaraju N, Khoury JD.

Cancers (Basel). 2019 May 19;11(5). pii: E695. doi: 10.3390/cancers11050695.

45.

Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study.

Ragon BK, Odenike O, Baer MR, Stock W, Borthakur G, Patel K, Han L, Chen H, Ma H, Joseph L, Zhao Y, Baggerly K, Konopleva M, Jain N.

Clin Lymphoma Myeloma Leuk. 2019 Jul;19(7):431-440.e13. doi: 10.1016/j.clml.2019.03.015. Epub 2019 Mar 26.

PMID:
31056348
46.

Photoacoustic-based oxygen saturation assessment of murine femoral bone marrow in a preclinical model of leukemia.

Wood C, Harutyunyan K, Sampaio DRT, Konopleva M, Bouchard R.

Photoacoustics. 2019 Feb 20;14:31-36. doi: 10.1016/j.pacs.2019.01.003. eCollection 2019 Jun.

47.

Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm.

Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, Rizzieri DA, Wang ES, Duvic M, Sloan JM, Spence S, Shemesh S, Brooks CL, Balser J, Bergstein I, Lancet JE, Kantarjian HM, Konopleva M.

N Engl J Med. 2019 Apr 25;380(17):1628-1637. doi: 10.1056/NEJMoa1815105.

PMID:
31018069
48.

Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.

Jabbour EJ, Sasaki K, Ravandi F, Short NJ, Garcia-Manero G, Daver N, Kadia T, Konopleva M, Jain N, Cortes J, Issa GC, Jacob J, Kwari M, Thompson P, Garris R, Pemmaraju N, Yilmaz M, O'Brien SM, Kantarjian HM.

Cancer. 2019 Aug 1;125(15):2579-2586. doi: 10.1002/cncr.32139. Epub 2019 Apr 15.

PMID:
30985931
49.

Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts.

Strati P, Garcia-Manero G, Zhao C, Kadia T, Borthakur G, Konopleva M, Daver N, DiNardo CD, Short NJ, Yilmaz M, Naqvi K, Alvarado Y, Pierce SA, Cortes J, Bueso-Ramos C, Kantarjian H, Ravandi F.

Am J Hematol. 2019 Jul;94(7):E188-E190. doi: 10.1002/ajh.25490. Epub 2019 Apr 29. No abstract available.

PMID:
30977182
50.

NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy.

Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Patel K, Ganan-Gomez I, Jabbour E, Kadia T, Ravandi F, DiNardo C, Borthakur G, Takahashi K, Konopleva M, Komrokji RS, DeZern A, Kuzmanovic T, Maciejewski J, Pierce S, Colla S, Sekeres MA, Kantarjian H, Bueso-Ramos C, Garcia-Manero G.

Blood Adv. 2019 Mar 26;3(6):922-933. doi: 10.1182/bloodadvances.2018026989.

Supplemental Content

Loading ...
Support Center